Art

J-GLOBAL ID：202002236991853197   Reference number：20A0591055

Immunotherapies in Huntington’s disease and α-Synucleinopathies

ハンチントン病とα-シヌクレイン症における免疫療法【JST・京大機械翻訳】

Author (9)： Fatoba Oluwaseun (Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita, Japan) ,  Fatoba Oluwaseun (WPI -Immunology Frontier Research Center, Osaka University, Suita, Japan) ,  Ohtake Yosuke (Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita, Japan) ,  Ohtake Yosuke (Department of Neuro-Medical Science, Graduate School of Medicine, Osaka University, Suita, Japan) ,  Itokazu Takahide (Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita, Japan) ,  Itokazu Takahide (Department of Neuro-Medical Science, Graduate School of Medicine, Osaka University, Suita, Japan) ,  Yamashita Toshihide (Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita, Japan) ,  Yamashita Toshihide (WPI -Immunology Frontier Research Center, Osaka University, Suita, Japan) ,  Yamashita Toshihide (Department of Neuro-Medical Science, Graduate School of Medicine, Osaka University, Suita, Japan)
Material： Frontiers in Immunology (Web)
Volume： 11  Page： 337  Publication year： 2020 
JST Material Number： U7074A  ISSN： 1664-3224  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Modulation of immune activatio...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0591055&from=J-GLOBAL&jstjournalNo=U7074A") }}

Thesaurus term： effectiveness ,  *Immunotherapy ,  *Huntington's disease ,  combination therapy ,  antibody ,  anti-inflammatory action ,  Proteins ,  Inflammation ,  targeting ,  *Synucleins ,  Immune System ,  Neurodegenerative Diseases ,  immune activation ,  *alpha-Synuclein
Semi thesaurus term： 神経変性 , 【Automatic Indexing@JST】

Author keywords (5)： Huntington’s disease ,  α-synucleinopathies ,  immune activation ,  immunotherapy ,  combination therapy

JST classification (2)： Immunotherapy for tumors  (GE03035B) ,  Immunological reaction in general  (ED03010T)

Reference (158)：

• Ashley CT Jr, Warren ST. Trinucleotide repeat expansion and human disease. Annu Rev Genet. (1995) 29:703-28. doi: 10.1146/annurev.ge.29.120195.003415
• Bates GP, Mangiarini L, Wanker EE, Davies SW. Polyglutamine expansion and Huntington's disease. Biochem Soc Trans. (1998) 26:471-5. doi: 10.1042/bst0260471
• Cummings CJ, Zoghbi HY. Fourteen and counting: unraveling trinucleotide repeat diseases. Hum Mol Genet. (2000) 9:909-16. doi: 10.1093/hmg/9.6.909
• Rüb U, Schöls L, Paulson H, Auburger G, Kermer P, Jen JC, et al. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog Neurobiol. (2013) 104:38-66. doi: 10.1016/j.pneurobio.2013.01.001
• Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. (1996) 87:493-506. doi: 10.1016/S0092-8674(00)81369-0

Terms in the title (3)： ハンチントン病 ,  α-シヌクレイン ,  免疫療法